Sugi Predict

Sugi Predict / Targets / CD209

CD209

CD209 antigen · Q9NNX6 · CD209 on Sugi Atlas →

6,227 patent compounds predicted against CD209, 4,026 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4653648 SCHEMBL4653648 0.64 3/20
SCHEMBL4653446 SCHEMBL4653446 0.61 3/20
SCHEMBL3636324 SCHEMBL3636324 0.57 3/20
SCHEMBL1923753 SCHEMBL1923753 0.51 3/20
SCHEMBL2300084 SCHEMBL2300084 0.51 3/20
SCHEMBL3516599 SCHEMBL3516599 0.51 3/20
SCHEMBL3924682 SCHEMBL3924682 0.51 3/20
SCHEMBL5545675 SCHEMBL5545675 0.51 3/20
SCHEMBL8254322 SCHEMBL8254322 0.51 3/20
SCHEMBL1239221 SCHEMBL1239221 0.51 3/20
SCHEMBL5336720 SCHEMBL5336720 0.51 3/20
SCHEMBL7560218 SCHEMBL7560218 0.47 3/20
SCHEMBL2926208 SCHEMBL2926208 0.45 3/20
SCHEMBL7106557 SCHEMBL7106557 0.44 3/20
SCHEMBL7106637 SCHEMBL7106637 0.44 3/20
SCHEMBL303328 SCHEMBL303328 0.44 3/20
SCHEMBL5049096 SCHEMBL5049096 0.44 3/20
SCHEMBL7141387 SCHEMBL7141387 0.44 3/20
SCHEMBL8446628 SCHEMBL8446628 0.44 3/20
SCHEMBL332798 SCHEMBL332798 0.43 3/20

Clinical trials — most relevant to CD209 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC PHASE2/PHASE3SUSPENDED
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma PHASE2WITHDRAWN
Rituximab in the Treatment of Graves' Disease PHASE1/PHASE2COMPLETED
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders PHASE2COMPLETED
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome PHASE1/PHASE2COMPLETED
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus PHASE1/PHASE2NOT_YET_RECRUITING
Combination CAR-T Cell Therapy Targeting Hematological Malignancies PHASE1/PHASE2RECRUITING
Topical Anti-Androgens in Pilonidal Sinus Disease PHASE2RECRUITING
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma PHASE1RECRUITING
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus PHASE1NOT_YET_RECRUITING
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma PHASE1UNKNOWN
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis PHASE1UNKNOWN
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies EARLY_PHASE1UNKNOWN
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression nanUNKNOWN
Evaluation of M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages. nanCOMPLETED
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry nanUNKNOWN
Cohort Study of Airway Microecology and the Pathogenesis and Evolution of Chronic Obstructive Pulmonary Disease nanACTIVE_NOT_RECRUITING
The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction nanUNKNOWN
Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy nanUNKNOWN
Treatment of Perianal Fistulas in Crohn's Disease With Autologous Microfragmented Adipose Tissue With the Lipogems System nanUNKNOWN
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases? nanUNKNOWN
Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma nanUNKNOWN
Postprandial Monocyte Study nanCOMPLETED
Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs nanRECRUITING
Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer nanUNKNOWN
Cancer Fusion Hybrids and Desmoplasia nanUNKNOWN
Thrombus Aspiration and Pathology and OCT Study nanRECRUITING
Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC nanCOMPLETED
Omics of Rituximab-resistance nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD209 binder may also engage these)

ProteinNameSimilarity
Q8HY01 — 1.000 Q8HY01 →
Q8HXZ7 — 1.000 Q8HXZ7 →
CLEC4M C-type lectin domain family 4 member M 1.000 landscape →
Q95J96 — 0.999 Q95J96 →
Q8HXZ8 — 0.998 Q8HXZ8 →
Q8HY02 — 0.998 Q8HY02 →
Q8HY00 — 0.997 Q8HY00 →
Q8HY11 — 0.997 Q8HY11 →
Q8HY04 — 0.997 Q8HY04 →
P60883 — 0.996 P60883 →
Q8HY12 — 0.995 Q8HY12 →
Q8HY03 — 0.995 Q8HY03 →
Q8HY10 — 0.994 Q8HY10 →
Q8HYC0 — 0.993 Q8HYC0 →
Q8HY06 — 0.991 Q8HY06 →
Q95LC6 — 0.991 Q95LC6 →
Q6ZS10 — 0.978 Q6ZS10 →
Q8CJ91 — 0.976 Q8CJ91 →
B4DH59 — 0.974 B4DH59 →
Q9UQP3 — 0.971 Q9UQP3 →
E9Q0N2 — 0.969 E9Q0N2 →
P20693 — 0.967 P20693 →
P0CG38 — 0.966 P0CG38 →
A5A3E0 — 0.965 A5A3E0 →
Q8MIS5 — 0.964 Q8MIS5 →
P0DKP4 — 0.963 P0DKP4 →
Q9EQ09 — 0.963 Q9EQ09 →
PRDM9 Histone-lysine N-methyltransferase PRDM9 0.962 landscape →
O70156 — 0.962 O70156 →
Q4VC44 — 0.962 Q4VC44 →